Aripiprazole (Abilify) for schizophrenia.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001007:Anxiety; D000068180:Aripiprazole; D018491:Dopamine Agonists / Q000493:pharmacokinetics / Q000494:pharmacology; D004347:Drug Interactions; D005252:Fees, Pharmaceutical; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology; D009325:Nausea / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy*; D013810:Therapeutic Equivalency
D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole